Health Catalyst Inc HCAT.OQ HCAT.O is expected to show a fall in quarterly revenue when it reports results on November 10 for the period ending September 30 2025
The South Jordan Utah-based company is expected to report a 0.6% decrease in revenue to $75.9 million from $76.35 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.The company's guidance on August 7 2025, for the period ended September 30, was for revenue of $75.000 million.
LSEG's mean analyst estimate for Health Catalyst Inc is for earnings of 6 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Health Catalyst Inc is $4.00, about 26% above its last closing price of $2.96
The company's guidance on August 7 2025 for the period ended September 30 was for Earnings before Interest, Taxes, Depreciation and Amortization of of USD10.5 million.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.03 | 0.03 | 0.04 | Beat | 18 |
Mar. 31 2025 | 0.00 | 0.00 | 0.01 | Beat | 400 |
Dec. 31 2024 | 0.07 | 0.07 | 0.04 | Missed | -45.9 |
Sep. 30 2024 | 0.10 | 0.10 | 0.07 | Missed | -28.3 |
Jun. 30 2024 | 0.09 | 0.08 | 0.12 | Beat | 51.3 |
Mar. 31 2024 | 0.03 | 0.03 | 0.05 | Beat | 79 |
Dec. 31 2023 | 0.01 | 0.00 | 0.02 | Beat | 2,700 |
Sep. 30 2023 | 0.00 | -0.02 | 0.03 | Beat | 275.6 |
This summary was machine generated November 7 at 21:20 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments